Rocatinlimab is a monoclonal antibody commercialized by Kyowa Kirin, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According to Globaldata, it is involved in 10 clinical trials, of which 5 were completed, 3 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Rocatinlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Rocatinlimab is expected to reach an annual total of $264 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Rocatinlimab Overview

Rocatinlimab is under development for the treatment of atopic dermatitis. The drug candidate is a new molecular entity (NME). It is administered through intravenous and subcutaneous infusion. It is a monoclonal antibody and acts by targeting OX40. The drug candidate is based on POTELLIGENT antibody engineering technology. It was also under development for the treatment of moderate plaque psoriasis and ulcerative colitis .

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY398,371 million for the fiscal year ended December 2022 (FY2022), an increase of 13.1% over FY2021. The operating profit of the company was JPY65,341 million in FY2022, compared to an operating profit of JPY60,055 million in FY2021. The net profit of the company was JPY53,572 million in FY2022, compared to a net profit of JPY52,347 million in FY2021.

For a complete picture of Rocatinlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.